Top 5 Performing Stocks To Watch For 2015

Sometimes even a stodgy life insurer needs some love, and Merrill Lynch has provided it in spades to Prudential (PRU).

NHLI via Getty Images Martin Brodeur plays at Prudential Center. Merrill Lynch makes the save. Or something like that.

That’s because Merrill Lynch’s Seth Weiss and Ian Ryave decided to upgrade Prudential today. They explain why:

We are upgrading Prudential from Neutral to Buy and raising our PO by 10% from $94 to $103. PRU has been the poorest performing life stock to start the year (down 6% vs. a 2% increase in S&P500 and a 1% increase in the median life name), and we view valuation as attractive. The increase in our PO is driven by 1) increased confidence that PRU can sustain an operating ROE at or above 14% and 2) new peaks in equity market suggesting a lower cost of equity for the industry.

Top Media Stocks To Buy For 2016: IsoRay Inc (ISR)

IsoRay, Inc. (IsoRay), incorporated on June 15, 2004, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. IsoRay International LLC (International) is a wholly owned subsidiary of the Company. IsoRay obtained clearance from the Food and Drug Association (FDA) for treatment for all solid tumor applications using Cesium-131. Such applications include prostate cancer; ocular melanoma; head, neck and lung tumors; breast cancer; liver cancer; brain cancer; colorectal cancer; gynecological cancer; esophageal cancer, and pancreatic cancer. The seed may be used in surface, interstitial and intracavity applications for tumors with known radio sensitivity. The Company has an existing distribution agreement with UralDial LLC (UralDial) that allows UralDial to distribute Proxcelan Cs-131 brachytherapy seeds in Russia. The Company, through UralDial, has regulatory approval to sell Cs-131 seeds in Russia.

IsoRay markets the Proxcelan Cesium-131 brachytherapy seed for the treatment of prostate cancer; lung cancer; ocular melanoma; head and neck cancers; colorectal cancer, brain cancer; and gynecological cancer. The Company focuses to market Cesium-131 for the treatment of other malignant disease, such as breast cancer, in the near future through the use of existing technologies that have received FDA-clearance. Cesium-131 is a radioactive isotope that can be produced by the neutron bombardment of Barium-130 (Ba-130). When placed into a nuclear reactor and exposed to a flux of neutrons, Ba-130 becomes Ba-131, the radioactive material that is the parent isotope of Cesium-131. The radioactive isotope Cesium-131 is normally produced by placing a quantity of stable non-radioactive barium (ideally barium enriched in isotope Ba-130) into the neutron flux of a nuclear reactor. The irradiation process converts a small fraction of this material into a radioactive form of barium (Ba-131). The Ba-131 decays by electron capture to the ! radioactive isotope of interest (Cesium-131).

As of June 30, 2011, IsoRay had agreements with several independent radiopharmacies to assay, preload, and sterilize loose seeds. During the fiscal year ended June 30, 2011, the Company loaded approximately 90% of Mick cartridges in the Company's own facility, which accounted for approximately 61% of seeds sold. Approximately 33% of seeds sold are strand configurations, including strands preloaded in needles and the remaining 6% of seeds are sold as loose seeds.

Advisors' Opinion:

• [By James E. Brumley]

  Ugh. It's fun to be right about a stock, but it's exhausting to be too right, too fast. Case in Point? IsoRay, Inc. (NYSE: ISR). Yours truly posted some bullish comments on ISR just a couple of days ago, explaining how that day's move above a key ceiling meant a new bull trend was underway, and more gains from that price would be far easier to muster. Well, good news for those who heeded the advice - IsoRay shares are up 44% today.

• [By James E. Brumley]

  I hate to be the one to say I told you so, but, I told you so. Back on February 26th I suggested IsoRay, Inc. (NYSEMKT:ISR) shares were a budding breakout play. The 48% rally that's played out for ISR in the meantime unfurled right on cue. While overbought in the very short run, this small cap stock looks like it's earning the right to be compared to the likes of bigger brothers in the cancer-treatment space... names like Roche Holding Ltd. (OTCMKTS:RHHBY) or Theragenics Corporation (NYSE:TGX).

• [By Vanina Egea]

  Strengthening portfolio and business stability is to be reinforced by the introduction of new products. Last December, Textron announced the successful first flight of the Scorpion Intelligence, Surveillance and Reconnaissance (ISR)/Strike aircraft. ��he Scorpion compares very favorably to more costly aircraft currently used for low-threat missions,��pilot Dan Hinson said. The new product is expected to accommodate the budget constraints and shifting mission requirements of the US Department of Defense. The same department has granted the firm an additional contract worth $22.5 million to "deprocess" Mobile Strike Force vehicles and train the Afghan Army.

Top 5 Performing Stocks To Watch For 2015: NMI Holdings Inc (NMIHZ)

NMI Holdings, Inc. (NMIH), incorporated on May 19, 2011, is a development-stage company. The Company through its subsidiaries provides private mortgage insurance in the United States. The Company�� wholly owned subsidiaries include National Mortgage Insurance Corporation and National Mortgage Reinsurance Inc One.

On April 24, 2012, NMI Holdings, Inc. (NMI) closed an agreement with MAC Financial Ltd. to acquire MAC Financial Holdings Corporation and its wholly owned subsidiaries. On September 30, 2013, the Company merged MAC Financial Holding Corporation into NMIH, with NMIH surviving the merger, and it merged NMRI Two into NMIC, with NMIC surviving the merger.

Advisors' Opinion:

• [By Zachary Tracer]

  NMI Holdings Inc. (NMIHZ), a mortgage insurer backed by funds tied to Carlyle Group LP (CG) and Kyle Bass, filed to sell shares in an initial public offering as investors bet on a housing-market rebound.

Top 5 Performing Stocks To Watch For 2015: Seacoast Banking Corporation of Florida(SBCF)

Seacoast Banking Corporation of Florida operates as the holding company for Seacoast National Bank that provides various financial products and services in the United States. It offers an array of deposit accounts and retail banking services; engages in consumer and commercial lending activities; and provides various trust and asset management services, as well as securities and annuity products to its customers. The company also offers marine loans. In addition, it provides Internet banking, and brokerage and annuity services. As of June 17, 2011, the company had 39 offices in South and Central Florida. Seacoast Banking Corporation of Florida was founded in 1926 and is based in Stuart, Florida.

Advisors' Opinion:

• [By Sean Williams]

  One that recently crossed my radar as an "avoid" is small-cap bank Seacoast Banking Corp. of Florida (NASDAQ: SBCF  ) �(henceforth known here as Seacoast to make our lives easier).

• [By James E. Brumley]

  Seacoast Banking Corporation of Florida (NASDAQ:SBCF) is certainly no Citigroup Inc. (NYSE:C) or Bank of America Corp. (NYSE:BAC), but then again, that may be a good thing - both larger banks are still dealing with the headaches of their sheer size. The smaller bank is far more nimble, and better still, appears to be on the verge of doling out a huge reward for shareholders.

Top 5 Performing Stocks To Watch For 2015: SPDR EURO STOXX 50 ETF (FEZ)

SPDR DJ Euro Stoxx 50 ETF (the Fund), formerly DJ Euro Stoxx 50 ETF, seeks to replicate as closely as possible the price and yield of the Dow Jones EURO STOXX 50 Index (the Index). The Index seeks to provide a blue-chip representation of the market sector leaders in the Eurozone. The Index represents the performance of the 50 largest companies within the Eurozone portion of the Dow Jones STOXX Total Market Index. The Index is a free-float market capitalization weighted index that captures approximately 60% of the underlying market and covers approximately 95% of the free-float market capitalization of the investable universe in the Eurozone.

The Fund utilizes a passive or indexing approach to invest in a portfolio of stocks to replicate the Index. The Fund�� investment advisor is SSgA Funds Management, Inc.

Advisors' Opinion:

• [By Chris Ciovacco]

  In Thursday's ETF analysis, evidence is presented that supports increasing demand for assets that get a tailwind from a weak U.S. dollar, including emerging markets (EEM) and foreign stocks (EFA). Casting a wider economic net, our market model told us to start buying stocks last week even with the threat of a U.S. default. Wednesday, we continued with our incremental allocation shifts by adding some exposure to the energy sector. Thursday, we sat tight holding long positions in small caps (IJR), Europe (FEZ), emerging markets and technology (QQQ). The upper bounds of the bullish S&P 500 trend channel shown below may offer some resistance to the market's near vertical ascent.

• [By Tom Aspray]

  The news out of the Eurozone continues to improve as their Purchasing Managers Index rose to 51.7 in August consistent with an expanding economy. The chart shows a nice trend here suggesting that the worst by indeed be over. A deeper pullback in some of the euro ETFs like SPDR Euro STOXX 50 ETF (FEZ) should create a buying opportunity.